High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

Löwenberg, Bob; J. Ossenkoppele, Gert; van Putten, Wim; C. Schouten, Harry; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Maertens, Johan; Jongen‐Lavrencic, Mojca; von Lilienfeld‐Toal, Marie; J. Biemond, Bart; Vellenga, Edo; van Marwijk Kooy, Marinus; F. Verdonck, Leo; Beck, Joachim; Döhner, Hartmut; Gratwohl, Aloïs; Pabst, Thomas; Verhoef, Gregor

doi:10.1056/nejmoa0901409

Public

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

Published in New England Journal of Medicine • Sep 23, 2009

Authors:

Bob Löwenberg

Gert J. Ossenkoppele

Wim van Putten

Abstract

BACKGROUND: A complete remission is essential for prolonging survival in patients with acute myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the optimal dose is unknown. In older patients, it is usual to give daunorubicin at a dose of 45 to 50 mg per square meter ...

Subject

Medicine

Daunorubicin

Cytarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!